Revance is launching Teoxane RHA Collection with mepivacaine, which will replace lidocaine as the anesthetic in the Collection in the U.S. market.

The Teoxane RHA Collection with mepivacaine received U.S. Food and Drug Administration (FDA) approval in 2023 and is exclusively patented by Teoxane for use in dermal fillers.

What Is Mepivacaine?

While new to the aesthetic market, mepivacaine has been widely used in therapeutic areas for more than 60 years. Mepivacaine features the same mechanism of action as lidocaine, with less local vasodilation, reducing the potential for injection-site reactions such as bruising. Preclinical and clinical studies comparing RHA Redensity with mepivacaine to RHA Redensity with lidocaine, as well as RHA 4 with mepivacaine to RHA 4 with lidocaine, found similar rheology, effective pain control, an established safety profile, and no change in aesthetic outcomes, Revance reports.

“Mepivacaine represents the first major advancement in pain management in fillers in nearly two decades,” says Valérie Taupin, Founder and CEO of Teoxane. “It provides an anesthetic effect comparable to currently available products, but with reduced local vasodilation, as demonstrated in the recent article published in RSC Pharmaceutics, 2025, which may result in less bruising. We are proud to bring this patented innovation to providers and offer great patient comfort.”